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Abstract
Background: Type I Interferons (IFNs) are well known cytokines which exert antiviral activity,
antitumor activity and immunomodulatory effects. Single-nucleotide polymorphisms (SNP) and
deletions in the gene coding for IFNA2 have been shown to influence the level of expression in vitro.
The indel polymorphism -305_-300delAACTTT showed the strongest effect in vitro. To analyse the
worldwide distribution of this polymorphism we analyzed five different populations (586
Vietnamese, 199 Central Africans, 265 Brazilians, 108 Kaingang and 98 Guarani). To investigate a
possible association with susceptibility to infectious diseases we determined the polymorphism in
malaria patients suffering either mild or severe malaria and in a cohort of hepatitis C virus infected
individuals.
Results: We could detect the indel polymorphism in all populations analysed. There was no
association with this polymorphism and the outcome of malaria but we found an increase of this
indel polymorphism in hepatitis C virus positive individuals compared to healthy controls (p =
0.014).
Conclusion: Polymorphisms in genes involved in the interferon pathway have been implicated in
the resistance or susceptibility against cerebral malaria and HBV. Here we show that an indel
polymorphism, which mediates a disadvantageous effect in HBV patients, may also play a
disadvantageous role in HCV infections stressing the importance of a fully functional interferon
pathway.
Background
Interferons (IFNs) constitute a family of secreted
cytokines, which are expressed as an early response to var-
ious stimuli [1] in the first line of defense against viral
infection [2]. The IFN family was originally recognized for
its capacity to protect naïve cells against viral infection
and IFN-α is known to play an important role in regulat-
ing and linking both the innate and the adaptive arms of
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immunity [3]. IFNs exhibit a broad diversity of biological
functions, as represented by three major biological activi-
ties: antiviral activity, antitumor activity and immu-
nomodulatory effects [4,5]. The type I IFN family in
humans comprise, in essence, 14 genes [6] coding for 13
interferons, and one IFN-beta and one IFN-omega [7].
They all lack introns and are clustered on the short arm of
the chromosome 9 [8]. The IFN genes express different
proteins that exhibit remarkably different activity profiles
[9] and especially IFN-α2 has an important impact on the
clinical field for the treatment of viral infections and dif-
ferent forms of cancer [6].
Recently it was shown that the genes IFNAR2 and IL10RB
involved in binding interferons or interleukin 10-related
cytokines, respectively were linked to persistence of hepa-
titis B virus in The Gambia [10]. This finding gave us a
rational to look at other genes involved in the interferon
pathway.
It has been shown that there is individual variation in the
production of IFN-α [11] which could be due to muta-
tions in the promoter of the IFNA2  gene. Song et al.
(2006) showed that naturally occurring alterations in the
promoter of this gene, especially the deletion -305_-
300delAACTTT, reduced the transcription of this gene in
vitro. This reduction could explain the individual differ-
ences in the interferon levels being one of the possible
causes of susceptibility of hepatitis B [12].
In this paper we examined the level of genetic differentia-
tion of the promoter of the IFNA2 gene by DNA sequenc-
ing and compared allele frequencies and genotype
distributions in populations from Central Africa (Gabon),
Brazil and Vietnam. One of these populations consisted of
patients having malaria of different severity (Central Afri-
cans) [13]; the other was affected by hepatitis C virus
(HCV) (Brazilians of Caucasian descent) [14]. With these
patient cohorts we sought to test the hypothesis whether
the indel polymorphism in the promoter of the IFNA2
gene is associated with disease outcome of other infec-
tious diseases. Healthy Amerindians were included to
investigate the frequency of this mutation and to detect a
possible factor leading to an increased risk to contract
infectious diseases [15].
Methods
Patients
1256 individuals were enrolled in this study at different
sites: 586 healthy blood donors from the ethnic group of
the Kinh at the Than Hung Dao Hospital in Hanoi as an
extension of the study described in [12], 199 Central Afri-
cans at the Albert Schweitzer Hospital in Lambarènè [13]
and 265 Brazilians of Caucasian origins at the Hospital de
Clinicas in Curitiba [14], 108 Kaingang and 98 Guarani
were recruited in their villages. Kaingang and Guarani are
the two major Amerindian tribes living in Southern Brazil
but despite living side by side for centuries the two groups
differ in many aspects of culture and genetics; e. g. HLA
type [16].
The Brazilians of European descent were either patients
enrolled in a hepatitis C treatment study (n = 101) or
healthy controls (n = 164) [14]. No patients had a history
of alcohol or drug abuse. Patients were included into the
study when HCV antibodies and HCV RNA was detected
in serum; the presence of HBV and HIV antibodies was an
exclusion criterion. From all patients biopsies were taken
and liver histology was assessed blindly by two patholo-
gists and staging of fibrosis.
Central Africans individuals were affected either by mild
(n = 100) or severe malaria (n = 99) [13]. Mild malaria
was characterised by a parasitaemia < 50,000 parasites/μl,
haemoglobin > 80 g/L, glucose > 50 mg/dL, lactate < 3
mmol/L, leukocytes < 12/nL, platelets > 50/nL, no sch-
izontaemia, and no signs of severe malaria such as cere-
bral malaria or other infections. The severely infected
children presented with severe anaemia or hyperparasitae-
mia as the main complications of clinical disease. Appro-
priate treatment with sulfadoxine/pyrimethamine was
given to mild cases. Severe cases were treated with intrave-
nous quinine plus clindamycin.
Amerindians were healthy subjects from a human genetics
study [17].
The genetic analysis was approved by the relevant ethic
committees of the involved institutions: the Institutional
Review Board of the Tran Hung Dao Hospital, Hanoi,
Vietnam; the ethics committee of the Medical Faculty in
Tübingen, Germany, the ethics committee of the Hospital
de Clínicas in Curitiba, Brazil and the ethics committees
of the International Foundation for the Albert Schweitzer
Hospital in Lambaréné, Gabon.
DNA extraction
Blood from all the participants was collected in EDTA
tubes and plasma was separated, aliquoted and stored at -
20°C for later use. Genomic DNA was extracted from
blood samples from using the QIAamp DNA blood kit
(Qiagen, Hilden, Germany), as described in the user man-
ual.
Polymerase chain reaction (PCR)
Genomic DNA was used as template for PCR. A single
fragment of 480 bp from the IFNA2 promoter was ampli-
fied using the following primer sets: IFN-F: 5'-
TTTCAAAAAAGTTGCTCTAAG-3', IFN-R: 5'-GTAGATGTT-
GCAGATGCTGCT-3' (Operon, Germany).BMC Genetics 2008, 9:80 http://www.biomedcentral.com/1471-2156/9/80
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All amplifications were initiated with a denaturing step of
94°C for 5 min, followed by 42 cycles of 94°C for 30 sec,
45°C for 30 sec annealing time and 72°C for 1 minute
elongation. The reaction was stopped after a final elonga-
tion step of 72°C for 10 min. A PTC-200 Peltier Termal
Cycler (Bio-Rad, Munich, Germany) was used to amplify
all the samples.
Genotyping
After purification, the respective PCR products were
sequenced with the same primers described above using
BigDye terminator chemistry on an ABI PRISM 3100
Genetic analyzer (Applied Biosystems, Foster City, USA).
The sequences were analyzed for polymorphisms in the
promoter of the IFNA2 gene after DNA alignment of the
sequenced products using the Bioedit alignment program
(North Carolina State University, USA). The quality of the
sequencing was assessed by visual inspection with refer-
ence to the electropherograms.
Statistical analysis
IFNA2 allele frequencies and genotype distributions for
each population as well as Hardy-Weinberg exact test were
calculated using the Genepop version 3.4 http://gene
pop.curtin.edu.au/.
Differences in allele frequencies and genotype distribu-
tions between populations were calculated using Fisher's
exact test using STATA http://www.stata.com/. P-value <
0.05 was considered to be significant.
Results
Allele frequency
Of the four mutations in the IFNA2 promoter only the
deletion -305_-300delAACTTT was analyzed because it
was shown to influence significantly the promoter activity
in vitro [12]. The frequency of this deletion in Central Afri-
cans, Brazilians, Guarani, Kaingang and Vietnamese is
presented in Table 1. Overall, 2512 alleles were analyzed,
and 2246 out of 2512 (90%) had no deletion while 266
(10%) of the alleles carried the deletion.
Allele frequencies at this locus were compared for the five
groups showing an irregular distribution in the different
populations (P < 0.001). Therefore pairwise comparison
of the allele frequencies was performed as shown in Table
2. The frequency of the deletion was significantly higher
in Brazilians than in any other population except for the
Guarani (P = 0.208). In Central Africans we find a signifi-
cantly lower frequency of this variant allele compared
with the rest of the populations except for Kaingang (P =
0.725).
Genotype distribution
The results of the observed genotype distribution in the
five populations are shown in Table 3. Among the 1256
individuals enrolled in the study, 1010 (80.4%) had no
deletion, 226 (18%) were heterozygous and 20 (1.6%)
carried the deletion on both chromosomes (Table 3). The
highest proportion of homozygous individuals carrying
the deletion was found in the Brazilian population (5%).
In contrast no homozygous individuals were found in the
Guarani being the population with the highest number of
heterozygous individuals. We performed pairwise com-
parison of the genotypes frequencies among the five
groups (Table 4). Brazilians and Guarani did not signifi-
cantly differ in genotype distribution whereas Central
Africans were significantly different from any of the pop-
ulations except for the Kaingang.
Hardy-Weinberg equilibrium
Expected genotype distributions were calculated using
GenePop for the position which was polymorphic in the
study populations (data not shown). The expected num-
bers did not significantly differ from the observed num-
bers in Central Africans, Guarani and Vietnamese,
suggesting that these populations were in Hardy-Wein-
berg equilibrium. In contrast, exact tests indicated that
expected and observed genotype distributions did signifi-
cantly differ in Brazilians and Kaingang, indicating that
these two groups are indeed in Hardy-Weinberg disequi-
librium (Table 5).
Association of the deletion Δ-300/-305 with clinical aspects
To determine the association of the deletion -305_-
300delAACTTT with different infectious diseases, we com-
pared the frequency of IFNA2 with clinical manifestation
of the diseases as well as with treatment outcome. No sig-
nificant association of the mutation with severity of
malaria (mild versus severe) were found in the Central
African populations (allelic frequencies of the deletion in
mild malaria cases 0.10 (90 individuals without deletion,
9 with the deletion on one chromosome) versus 0.12 in
severe cases (89 individuals without deletion, 9 with the
deletion on one chromosome, 1 individual with the dele-
tion on both chromosomes, P = 1). There was a statisti-
cally significant association with the manifestation of
Table 1: Number of alleles and frequency of the indel 
polymorphism in the IFNA2 promoter in five populations.
Major allele del -301/-306 Total
Central Africans 376 (0.94) 22 (0.06) 398
Brazilians 447 (0.84) 83 (0.16) 530
Guarani 173 (0.88) 23 (0.12) 196
Kaingang 202 (0.93) 14 (0.07) 216
Vietnamese 1048 (0.89) 124 (0.11) 1172
Total 2246 (0.90) 266 (0.10) 2512
Data are given in numbers of chromosomes analysed and frequencies 
in brackets.
del -301/-306 indicates the polymorphism -305_-300delAACTTT.BMC Genetics 2008, 9:80 http://www.biomedcentral.com/1471-2156/9/80
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HCV in Brazilians of Caucasian descent. We found among
101 HCV positive individuals 68 (67%) without deletion
on any chromosome; 30 (30%) with a deletion on one
chromosome and 3 (3%) with a deletion on both chro-
mosomes. In the healthy control group we had in a total
of 265 individuals 127 (77%) with no deletion on any
chromosome; 27 (17%) with a deletion on one chromo-
some and 10 (6%) with a deletion on both chromosomes.
The difference in the distribution is statistically significant
(p = 0.03). When looking at the heterozygous individuals
we find an odds ratio of 2 (CI = 1–4; p = 0.014) when we
compare patients with healthy controls. The deletion was
not found to be significantly associated with the treatment
success of IFN-α with or without ribavirin in hepatitis C
patients (data not shown).
Discussion
In this study we analyse a widely distributed chromo-
somal deletion in the promoter of the IFNA2 gene in five
cohorts. It has been shown that the deletion -305_-
300delAACTTT is associated with the clinical presentation
of hepatitis B and a lower expression level in vitro [12].
Here we investigated a possible influence of this deletion
in malaria and hepatitis C. There is evidence that IFN-α
can induce NOS2 expression and NO production by
human mononuclear cells in vitro and in vivo [18]. Also
NO has been reported to have antiviral activity for a vari-
ety of viruses [19] and to play an important role in malaria
[13,20]. Vigário et al. have shown that recombinant
human IFN-α inhibits cerebral malaria and reduces para-
site burden in mice [21].
Additionally, IFN-α, either alone or in combination with
ribavirin, is currently the standard treatment of patients
with hepatitis C [22]. Therefore we speculated that the
individual level of IFN-α depending on the promoter
activity of the gene might affect the outcome of malaria or
the therapy success in hepatitis C. In the latter event the
intrinsic production would have supported the externally
given IFN-α. We could not detect an influence of this pol-
ymorphism in Central Africans children with malaria. To
detect a statistically significant distribution with frequen-
cies in the malaria cohorts of 0.12 and 0.10 much larger
cohorts would be needed.
Treatment success of HCV infection was not influenced by
the presence of the polymorphism. We could, however,
detect a difference in distribution of genotypes in HCV
positive and healthy individuals. This finding confirms an
earlier observation in hepatitis B patients stressing the
importance of IFNA2 expression in these diseases.
The populations studied here diverged a long time ago
and have undergone diverse selective pressure, explaining
the genetic differences or similarities between groups. This
indel polymorphism probably has an ancient origin and
has entered the American continent 30.000 years ago [23]
with the migration wave from Asia. Vietnamese and the
two Amerindian groups, Kaingang and Guarani, therefore
do not differ significantly in the genotype distribution.
The Kaingang, unlike all other groups, do not show a sig-
nificantly different genotype distribution to the Central
Africans population, furthermore the Kaingang also
Table 2: Pairwise comparison of the allele frequency of the indel polymorphism in the IFNA2 promoter.
POPULATION Brazilians Guarani Kaigang Vietnamese Central Africans
Brazilians -- -- -- -- --
Guarani 0.208 -- -- -- --
Kaingang < 0.001 0.080 -- -- --
Vietnamese 0.004 0.609 0.072 -- --
Central Africans < 0.001 0.013 0.725 0.004 --
Given are P-values obtained by Fisher's test.
Table 3: Genotypic distribution of the indel polymorphism in the IFNA2 promoter in five populations.
wt/wt wt/del -301/-306 del -301/-306/del -301/-306 Total
Central Africans 178 (89.5) 20 (10) 1 (0.5) 199 (100)
Brazilians 195 (73.5) 57 (21.5) 13 (5) 265 (100)
Guarani 75 (76.5) 23 (23.5) 0 (0) 98 (100)
Kaingang 96 (88.9) 10 (9.3) 2 (1.8) 108 (100)
Vietnamese 466 (79.5) 116 (19.8) 4 (0.7) 586 (100)
Total 1010 (80.4) 226 (18) 20 (1.6) 1256 (100)
Data are given in number with percentages in brackets. del -301/-306 indicates the polymorphism -305_-300delAACTTT. wt indicates the major 
allele.BMC Genetics 2008, 9:80 http://www.biomedcentral.com/1471-2156/9/80
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diverge from the Hardy-Weinberg equilibrium. This find-
ing is partly due to the traffic of slaves to South America
during the 16th to the 19th  century and a subsequent
absorption of escaped African slaves by the Kaingang. By
comparing blood groups and protein polymorphisms it
was shown that Kaingang population had a higher pro-
portion of non-Amerindian alleles than the Guaranis
[24]. We found also a violation of the Hardy-Weinberg
equilibrium in Brazilian, which is probably due to admix-
ture in this area caused by the migration of individuals
from different parts of Europe [25].
Conclusion
The polymorphism analysed in this work influences the
course of hepatitis B and the prevalence of HCV. The treat-
ment success in hepatitis C was not influenced by this
indel polymorphism. Obviously, the externally given
IFNα concentration is much higher than the intrinsic pro-
duction of the patients. However, the fact that the indel
polymorphism has is more frequently present in hepatitis
B and C viruses argues for the importance of the IFNα
pathway in both viral infections.
Human malaria was not influenced by the indel polymor-
phism; IFNα probably plays a role at the beginning of an
infection but not at later time points when the parasite has
manifested itself.
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